{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
adenosine
to a specific field?
Status:
Investigational
Source:
NCT00568945: Phase 2 Interventional Completed Atrial Fibrillation
(2008)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Conditions:
Capadenoson (BAY 68-4986) is a nonnucleoside agonist for the A1 Adenosine Receptor (A1AR) and the A2BAR. Capadenoson has undergone two Phase IIa clinical trials, initially in patients with atrial fibrillation and subsequently in patients with stable angina. Capadenoson has also been shown to decrease cardiac remodeling in an animal model of advanced heart failure and a capadenoson derivative, neladenoson bialanate, recently entered clinical development for the treatment of chronic heart failure. The therapeutic effects of capadenoson are currently thought to be mediated through the A1AR.
Status:
Investigational
Source:
NCT00160134: Phase 2 Interventional Completed Congestive Heart Failure
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Conditions:
Derenofyllin (SLV320) is a selective adenosine A1 receptor antagonist, which is under investigation for the treatment of heart failure with renal dysfunction. Adverse events considered related to SLV320 were dizziness, nausea, transient hypertension and transient hypotension.
Status:
Investigational
Source:
NCT03217825: Phase 2 Interventional Completed Hypertension
(2015)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Conditions:
Rostafuroxin (PST 2238) is a digitoxygenin derivative, which selectively displaces ouabain from the Na ,K -ATPase receptor. PST 2238, at concentrations up to 10−4 M, did not show any significant interaction with a- and b-adrenergic, D1, D2, D3, 5-HT1, 5-HT2, H1, H2, M1, M2, A1, A2, Ca2 , Na , or K channel–associated receptors, AT1, AT2, ETa, ETb, GABA, thromboxane, vasopressin, angiotensin II, or the steorid-hormone receptors (androgen, progestogen, estrogen and mineralocorticoid), confirming that PST 2238 is specific for Na ,K -ATPase. Rostafuroxin has been developed in an attempt to unravel the contribution of mutated adducin and endogenous ouabain in the pathogenesis of hypertension. The compound lowered blood pressure in Milan hypertensive rats and humans. Rostafuroxine had been in phase II clinical trials for the treatment of hypertension. Following adverse events in Rostafuroxin group were described: dizziness, headache, upper respiratory tract infections, high blood pressure.
Status:
Investigational
Source:
NCT00430300: Phase 2 Interventional Terminated Pulmonary Disease, Chronic Obstructive
(2007)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
Conditions:
UK-432097 is a selective adenosine A2a agonist which was in development with Pfizer as an inhaled treatment for asthma and chronic obstructive pulmonary disease. UK-432097 had been in phase II clinical trials by Pfizer for the treatment of chronic obstructive pulmonary disease (COPD). However, this study was terminated prematurely due to futility based on results of interim analysis.
Status:
Investigational
Source:
NCT00312364: Phase 2 Interventional Completed Foot Ulcer, Diabetic
(2005)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Sonedenoson (MRE0094) is a topical adenosine A2A-receptor agonist which was under clinical development for the treatment of for diabetic foot ulcer. The compound was originally developed by New York University, and licensed to Medco Research (King Pharmaceuticals). King Pharmaceuticals was acquired by Pfizer in 2010. Sonedenoson has been in phase II clinical trials for the treatment of chronic diabetic neuropathic foot ulcers. However, this research has been discontinued.
Status:
Investigational
Source:
NCT00040001: Phase 2 Interventional Completed Atrial Fibrillation
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Selodenoson (formerly DTI-0009) was developed by Aderis Pharmaceutical as a selective adenosine A1 full agonist to control heart rate in patients with atrial fibrillation while minimizing changes in blood pressure or decreases in heart function. The drug was studied in phase II clinical trial to treat the patients with supraventricular arrhythmias, however, this study was discontinued.
Status:
Investigational
Source:
NCT01313572: Phase 3 Interventional Terminated Coronary Artery Disease
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Apadenoson (BMS-068645) is a selective adenosine 2A agonist that contains a methyl ester group which undergoes esterase hydrolysis to its acid metabolite. Apadenoson had been in phase III clinical trials by Forest (now a part of Allergan) for the treatment of coronary artery disease. However, this study has been terminated.
Class (Stereo):
CHEMICAL (ACHIRAL)
Midaxifylline, a potent and selective xanthine adenosine A1 receptor antagonist, was investigated for the treatment of Alzheimer's disease, cardiovascular disorders, kidney disorders, and major depressive disorder. However, all studies were discontinued.
Class (Stereo):
CHEMICAL (ACHIRAL)
Targets:
Enprofylline is a xanthine derivative that shares theophylline's bronchodilator properties. It can be considered a relatively selective, though not potent adenosine A2B receptors antagonist. Enprofylline is used in asthma, chronic obstructive pulmonary disease, and in the management of cerebrovascular insufficiency, sickle cell disease, and diabetic neuropathy. Long-term enprofylline administration may be associated with the elevation in liver enzyme levels and unpredictable blood levels.
Status:
Investigational
Source:
INN:naxifylline [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Naxifylline [CVT 124, BG 9719], a small molecule diuretic, is one of a new class of potent and highly selective adenosine A1 receptor antagonists discovered at University of Florida. Naxifylline is an A1 adenosine receptor antagonist used for the treatment of edema associated with congestive heart failure. Naxifylline appears to be one of the more potent and clearly the most A1-selective antagonist reported to date, with K1 values of 0.67 and 0.45 nM, respectively, at the rat and cloned human A1-receptors and with 1800-fold (rat) and 2400-fold (human) subtype selectivity. Naxifylline protects against the decline in renal function observed with diuretic therapy by promoting urine output.
